Acute activation of cannabinoid receptors by anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice

Diabetes

Volumn 64, Issue 3, 2015, Pages 808-818

  Troy Fioramonti, Stephanie ^a   Demizieux, Laurent ^a   Gresti, Joseph ^a   Muller, Tania ^a   Vergès, Bruno ^a   Degrace, Pascal ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MESSENGER RNA; PHLORETIN; PHLORIZIN; RIMONABANT; XYLOSE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; ENDOCANNABINOID; GLUCOSE BLOOD LEVEL; INDOLE DERIVATIVE; IODOPRAVADOLINE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; DUODENUM; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; STEADY STATE; STOMACH EMPTYING; ANIMAL; C57BL MOUSE; DRUG EFFECTS; METABOLISM; POSTPRANDIAL STATE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; BLOOD GLUCOSE; ENDOCANNABINOIDS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HYPERGLYCEMIA; INDOLES; MALE; MICE; MICE, INBRED C57BL; PIPERIDINES; POLYUNSATURATED ALKAMIDES; POSTPRANDIAL PERIOD; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84928030855     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0721     Document Type: Article

References (50)

1. Howlett AC, Blume LC, Dalton GD. CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem 2010;17:1382-1393
2. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006;30(Suppl. 1):S13-S18
3. Wang J, Ueda N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat 2009;89:112-119
4. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-825
5. Silvestri C, Di Marzo V. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013;17:475-490
6. Di Marzo V, Després JP. CB1 antagonists for obesity - what lessons have we learned from rimonabant? Nat Rev Endocrinol 2009;5:633-638
7. Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010;59:926-934
8. Nogueiras R, Veyrat-Durebex C, Suchanek PM, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008;57:2977-2991
9. Chanda D, Kim DK, Li T, et al. Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes. J Biol Chem 2011;286:27971-27979
10. Liu J, Zhou L, Xiong K, et al. Hepatic cannabinoid receptor-1 mediates dietinduced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142:1218.e1-1228.e1
11. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118:3160-3169
12. Casu MA, Porcella A, Ruiu S, et al. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur J Pharmacol 2003;459:97-105
13. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002;448:410-422
14. Croci T, Manara L, Aureggi G, et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 1998;125:1393-1395
15. Di Marzo V, Capasso R, Matias I, et al. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 2008;153:1272-1280
16. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 2007;152:663-670
17. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993;36:857-862
18. Jones KL, Horowitz M, Wishart MJ, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J Nucl Med 1995;36:2220-2228
19. Schwartz MP, Samsom M, Renooij W, et al. Small bowel motility affects glucose absorption in a healthy man. Diabetes Care 2002;25:1857-1861
20. Leiter LA, Ceriello A, Davidson JA, et al.; International Prandial Glucose Regulation Study G: Postprandial glucose regulation: new data and new implications. Clin Ther 2005;27(Suppl. B):S42-S56
21. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998;19:583-592
22. Wagner B, Galey WR. Kinetic analysis of hexose transport to determine the mechanism of amygdalin and prunasin absorption in the intestine. J Appl Toxicol 2003;23:371-375
23. Yamada K, Hosokawa M, Fujimoto S, et al. The spontaneously diabetic Torii rat with gastroenteropathy. Diabetes Res Clin Pract 2007;75:127-134
24. Jourdan T, Demizieux L, Gresti J, et al. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants. Hepatology 2012;55:790-799
25. Antunes DM, da Costa JP, Campos SM, et al. The serum D-xylose test as a useful tool to identify malabsorption in rats with antigen specific gut inflammatory reaction. Int J Exp Pathol 2009;90:141-147
26. Hediger MA, Rhoads DB. Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994;74:993-1026
27. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;46:791-796
28. Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci 2011; 1243:E55-E74
29. Capasso R, Matias I, Lutz B, et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005;129:941-951
30. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002;123:227-234
31. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008;153:263-270
32. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008;57:1140-1155
33. Drozdowski LA, Thomson AB. Intestinal sugar transport. World J Gastroenterol 2006;12:1657-1670
34. Chaudhry RM, Scow JS, Madhavan S, Duenes JA, Sarr MG. Acute enterocyte adaptation to luminal glucose: a posttranslational mechanism for rapid apical recruitment of the transporter GLUT2. J Gastrointest Surg 2012;16:312-319; discussion 319
35. Kellett GL. The facilitated component of intestinal glucose absorption. J Physiol 2001;531:585-595
36. Zheng Y, Scow JS, Duenes JA, Sarr MG. Mechanisms of glucose uptake in intestinal cell lines: role of GLUT2. Surgery 2012;151:13-25
37. Gonçalves P, Araújo JR, Azevedo I, Martel F. Lack of a significant effect of cannabinoids upon the uptake of 2-deoxy-D-glucose by Caco-2 cells. Pharmacology 2008;82:30-37
38. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157
39. Holst JJ. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004;9:155-166
40. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008;151:123-129
41. Ogawa E, Hosokawa M, Harada N, et al. The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice. Biochem Biophys Res Commun 2011;404:115-120
42. Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A 1999;96:14228-14233
43. Duncan M, Mouihate A, Mackie K, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharidetreated rats. Am J Physiol Gastrointest Liver Physiol 2008;295:G78-G87
44. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004;142:1247-1254
45. Mulè F, Amato A, Baldassano S, Serio R. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol Res 2007;56:185-192
46. Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD. Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol 2002;80:67-76
47. Bolognini D, Cascio MG, Parolaro D, Pertwee RG. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol 2012; 165:2561-2574
48. Iannotti FA, Piscitelli F, Martella A, et al. Analysis of the "endocannabinoidome" in peripheral tissues of obese Zucker rats. Prostaglandins Leukot Essent Fatty Acids 2013;89:127-135
49. Capasso R, Izzo AA. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. J Neuroendocrinol 2008;20(Suppl. 1):39-46
50. Osei-Hyiaman D, Harvey-White J, Bátkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes (Lond) 2006;30(Suppl. 1):S33-S38